RVTY · Revvity

S&P 500 #467 · NYSE

Risiko 5/10 · Life Science Tools · $111.51 ▲ 3.18%

Kennzahlen

• Price $111.51
• Market cap $12.4B
• P/E (ttm) 53.87
• Div yield 0.26%
• 52-wk range $81.22 – $118.30
• Index rank #467 / —

Wichtigste Risiken

• Biotech/pharma R&D spending slowdown post-COVID (Instruments demand) — HIGH
• China exit/divestiture creating revenue gap (Near-term growth) — HIGH
• High P/E (47x) leaves little room for earnings misses (Valuation) — MED
• NIH/academic funding cuts under budget pressure (Research customer spending) — MED

Fazit

Life science tools and diagnostics company (formerly PerkinElmer) refocusing on higher-margin genomics and detection; portfolio pruning ongoing with China exit.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.